Bibliography
- CAPLEN NJ, PARRISH S, IMANI F, FIRE A, MORGAN RA: Specific inhibition of gene expression by small double-stranded RNAs in invertebrate and vertebrate systems. Proc. Natl. Acad. Sci. USA (2001) 98:9742–9747.
- ELBASHIR SM, HARBORTH J, LENDECKEL W et al.: Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature (2001) 411:494–498.
- PADDISON PJ, HANNON GJ: RNA interference: the new somatic cell genetics? Cancer Cell (2002) 2:17–23.
- PADDISON PJ, HANNON GJ: siRNAs and shRNAs: skeleton keys to the human genome. Curr. Opin. Mol. Ther. (2003) 5:217–224.
- SCHERR M, MORGAN MA, EDER M:Gene silencing mediated by small interfering RNAs in mammalian cells. Curr. Med. Chem. (2003) 10:245–256.
- SHI Y: Mammalian RNAi for the masses. Trends Genet. (2003) 19:9–12.
- SHUEY DJ, MCCALLUS DE, GIORDANO T: RNAi: gene-silencing in therapeutic intervention. Drug Discov. Today (2002) 7:1040–1046.
- WALL NR, SHI Y: Small RNA: can RNA interference be exploited for therapy? Lancet (2003) 362:1401–1403.
- CAPLEN NJ: RNAi as a gene therapy approach. Expert Opin. Biol. Ther. (2003) 3:575–586.
- AGAMI R: RNAi and related mechanisms and their potential use for therapy. Can: Opin. Chem. Biol. (2002) 6:829–834.
- LIEBERMAN J, SONG E, LEE SK, SHANKAR P: Interfering with disease: opportunities and roadblocks to harnessing RNA interference. Trends Mol. Med. (2003) 9:397–403.
- PADDISON PJ, CAUDY AA, BERNSTEIN E, HANNON GJ, CONKLIN DS: Short hairpin RNAs (shRNAs) induce sequence-specific silencing in mammalian cells. Genes Dev. (2002) 16:948–958.
- SUI G, SOOHOO C, AFFAR EL B et al.:A DNA vector-based RNAi technology to suppress gene expression in mammalian cells. Proc. Natl. Acad. Sci. USA (2002) 99:5515–5520.
- YU JY, DERUITER SL, TURNER DL: RNA interference by expression of short-interfering RNAs and hairpin RNAs in mammalian cells. Proc. Nati Acad. Set. USA (2002) 99:6047–6052.
- MIYAGISHI M, TAIRA K: U6 promoter-driven siRNAs with four uridine 3' overhangs efficiently suppress targeted gene expression in mammalian cells. Nat. Biotechnol. (2002) 20:497–500.
- PAUL CP, GOOD PD, WINER I, ENGELKE DR: Effective expression of small interfering RNA in human cells. Nat. Biotechnol. (2002) 20:505–508.
- KWAK YD, KOIKE H, SUGAYA K: RNA Interference with small hairpin RNAs transcribed from a human U6 promoter- driven DNA vector. Pharmacol. Sri. (2003) 93:214–217.
- BRUMMELKAMP TR, BERNARDS R, AGAMI R: A system for stable expression of short interfering RNAs in mammalian cells. Science (2002) 296:550–553.
- BODEN D, PUSCH O, LEE F et al.: Promoter choice affects the potency of HIV-1 specific RNA interference. Nucleic Acids Res. (2003) 31:5033–5038.
- KAWASAKI H, TAIRA K: Short hairpin type of dsRNAs that are controlled by tRNA(Val) promoter significantly induce RNAi-mediated gene silencing in the cytoplasm of human cells. Nucleic Acids Res. (2003) 31:700–707.
- XIA H, MAO Q, PAULSON HL, DAVIDSON BL: siRNA-mediated gene silencing in vitro and in vivo. Nat. Biotechnol. (2002) 20:1006–1010.
- DEVROE E, SILVER PA: Retrovirus-delivered siRNA. BMC Biotechnol. (2002) 2:15.
- BRUMMELKAMP TR, BERNARDS R, AGAMI R: Stable suppression of tumorigenicity by virus-mediated RNA interference. Cancer Cell (2002) 2:243–247.
- ••Demonstrates that retroviral RNAi vectorscan selectively silence the K-RASV12 oncogene and completely block tumour formation in nude mice.
- BARTON GM, MEDZHITOV R: Retroviral delivery of small interfering RNA into primary cells. Proc. Nati Acad. Sci. USA (2002) 99:14943–14945.
- ABBAS-TERKI T, BLANCO-BOSE W, DEGLON N, PRALONG W, AEBISCHER P: Lentiviral-mediated RNA interference. Hum. Gene Ther. (2002) 13:2197–2201.
- RUBINSON DA, DILLON CP, KWIATKOWSKI AV et al.: A lentivirus-based system to functionally silence genes in primary mammalian cells, stem cells and transgenic mice by RNA interference. Nat. Genet. (2003) 33:401–406.
- •One of several reports describing the use of lentiviral RNAi vectors to generate knockdown mice.
- STEWART SA, DYKXHOORN DM, PALLISER D et al.: Lentivirus-delivered stable gene silencing by RNAi in primary cells. RNA (2003) 9:493–501.
- TISCORNIA G, SINGER O, IKAWA M, VERIVIA IM: A general method for gene knockdown in mice by using lentiviral vectors expressing small interfering RNA. Proc. Nati Acad. Sci. USA (2003) 100:1844–1848.
- •One of several reports describing the use of lentiviral RNAi vectors to generate knockdown mice.
- MATTA H, HOZAYEV B, TOMAR R, CHUGH P, CHAUDHARY PM: Use of lentiviral vectors for delivery of small interfering RNA. Cancer Biol. Ther. (2003) 2:206–210.
- SCHERR M, BATTMER K, GANSER A,EDER M: Modulation of gene expression by lentiviral-mediated delivery of small interfering RNA. Cell Cycle (2003) 2:251–257.
- AN DS, XIE Y, MAO SH et al.: Efficient lentiviral vectors for short hairpin RNA delivery into human cells. Hum. Gene Tiler: (2003) 14:1207–1212.
- WIZNEROWICZ M, TRONO D: Conditional suppression of cellular genes: lentivirus vector-mediated drug-inducible RNA interference. J. Virol. (2003) 77:8957–8961.
- •Demonstrates that lentiviral RNAi vectors can be adapted for inducible siRNA expression.
- SHEN C, BUCK AK, LIU X, WINKLER M, RESKE SN: Gene silencing by adenovirus-delivered siRNA. FEBS Lett. (2003) 539:111–114.
- ARTS GJ, LANGEMEIJER E, TISSINGH R et al.: Adenoviral vectors expressing siRNAs for discovery and validation of gene function. Genome Res. (2003) 13:2325–2332.
- ZHAO LJ, JIAN H, ZHU H: Specific gene inhibition by adenovirus-mediated expression of small interfering RNA. Gene (2003) 316:137–141.
- TOMAR RS, MATTA H, CHAUDHARY PM: Use of adeno-associated viral vector for delivery of small interfering RNA. Oncogene (2003) 22:5712–5715.
- LEWIS PF, EMERMAN M: Passage through mitosis is required for oncoretroviruses but not for the human immunodeficiency virus. J. Virol. (1994) 68:510–516.
- HATZIIOANNOU T, GOFF SP: Infectionof nondividing cells by Rous sarcoma virus. Virol. (2001) 75:9526–9531.
- LEWIS P, HENSEL M, EMERMAN M: Human immunodeficiency virus infection of cells arrested in the cell cycle. EMBO (1992) 11:3053–3058.
- QIN XF, AN DS, CHEN IS, BALTIMORE D: Inhibiting HIV-1 infection in human T cells by lentiviral-mediated delivery of small interfering RNA against CCR5. Proc. Natl. Acad. Sci. USA (2003) 100:183–188.
- •One of a series of reports demonstrating that lentiviral RNAi vectors can inhibit HIV replication in primary human T cells.
- LI MJ, BAUER G, MICHIENZI A et al.: Inhibition of HIV-1 infection by lentiviral vectors expressing Pol III-promoted anti-HIV RNAs. Mol. Ther. (2003) 8:196–206.
- •One of a series of reports demonstrating that lentiviral RNAi vectors can inhibit HIV replication in primary human T cells.
- MALIM MH, HAUBER J, LE SY, MAIZEL JV, CULLEN BR: The HIV-1 rev trans-activator acts through a structured target sequence to activate nuclear export of unspliced viral mRNA. Nature (1989) 338:254–257.
- FELBER BK, HADZOPOULOU-CLADARAS M, CLADARAS C, COPELAND T, PAVLAKIS GN: rev protein of human immunodeficiency virus Type 1 affects the stability and transport of the viral mRNA. Proc. Natl. Acad. Sci. USA (1989) 86:1495–1499.
- PARK F, KAY MA: Modified HIV-1 basedlentiviral vectors have an effect on viral transduction efficiency and gene expression in vitro and in vivo. Mol. The]: (2001) 4:164–173.
- ZUFFEREY R, DONELLO JE, TRONO D, HOPE TJ: Woodchuck hepatitis virus posttranscriptional regulatory element enhances expression of transgenes delivered by retroviral vectors. Vim/. (1999) 73:2886–2892.
- CHI JT, CHANG HY, WANG NN et al.: Genomewide view of gene silencing by small interfering RNAs. Proc. Nati Acad. Sci. USA (2003) 100:6343–6346.
- SEMIZAROV D, FROST L, SARTHY A et al.: Specificity of short interfering RNA determined through gene expression signatures. Proc. Nati Acad. Sri. USA (2003) 100:6347–6352.
- JACKSON AL, BARTZ SR, SCHELTER J et al.: Expression profiling reveals off-target gene regulation by RNAi. Nat. Biotechnol. (2003) 21:635–637.
- ••Suggests that siRNA may induce off-targetgene silencing.
- BRIDGE AJ, PEBERNARD S, DUCRAUX A, NICOULAZ AL, IGGO R: Induction of an interferon response by RNAi vectors in mammalian cells. Nat. Genet. (2003) 34:263–264.
- ••Demonstrates that RNAi vectors mayinduce an interferon response.
- SLEDZ CA, HOLKO M, DE VEER MJ, SILVERMAN RH, WILLIAMS BR: Activation of the interferon system by short-interfering RNAs. Nat. Cell Biol. (2003) 5:834–839.
- ••Demonstrates that siRNA may induce aninterferon response.
- MACKENZIE TC, KOBINGER GP, KOOTSTRA NA et al: Efficient transduction of liver and muscle after in utero injection of lentiviral vectors with different pseudotypes. MM. Ther. (2002) 6:349–358.
- •One of several noteworthy papers demonstrating that pseudotyping can dramatically alter lentiviral tropism in vivo.
- KANG Y, STEIN CS, HETH JA et al.: In vivo gene transfer using a nonprimate lentiviral vector pseudotyped with Ross River Virus glycoproteins.J. Virol (2002) 76:9378–9388.
- •One of several noteworthy papers demonstrating that pseudotyping can dramatically alter lentiviral tropism in vivo.
- MARTIN F, NEIL S, KUPSCH J et al.: Retrovirus targeting by tropism restriction to melanoma cells." Virol (1999) 73:6923–6929.
- NGUYEN TH, LOUX N, DAGHER I et al.: Improved gene transfer selectivity to hepatocarcinoma cells by retrovirus vector displaying single-chain variable fragment antibody against c-Met. Cancer Gene Ther. (2003) 10:840–849.
- MORIZONO K, BRISTOL G, XIE YM, KUNG SK, CHEN IS: Antibody-directed targeting of retroviral vectors via cell surface antigens.Virol (2001) 75:8016–8020.
- GOLLAN TJ, GREEN MR: Selective targeting and inducible destruction of human cancer cells by retroviruses with envelope proteins bearing short peptide ligands." Virol (2002) 76:3564–3569.
- GOLLAN TJ, GREEN MR: Redirecting retroviral tropism by insertion of short, nondisruptive peptide ligands into envelope. Virol (2002) 76:3558–3563.
- BUPP K, ROTH MJ: Targeting a retroviral vector in the absence of a known cell- targeting ligand. Hum. Gene Ther. (2003) 14:1557–1564.
- •Presents a selection scheme for altering tropism by screening a library of envelopes containing random peptide insertions.
- JACQUE JM, TRIQUES K, STEVENSON M: Modulation of HIV-1 replication by RNA interference. Nature (2002) 418:435–438.
- LEE NS, DOHJIMA T, BAUER Get al.:Expression of small interfering RNAs targeted against HIV-1 rev transcripts in human cells. Nat. Biotechnol (2002) 20:500–505.
- SURABHI RM, GAYNOR RB: RNA interference directed against viral and cellular targets inhibits human immunodeficiency virus type 1 replication.
- •Virol (2002) 76:12963–12973.
- COBURN GA, CULLEN BR: Potent and specific inhibition of human immunodeficiency virus type 1 replication by RNA interference." Virol (2002) 76:9225–9231.
- NOVINA CD, MURRAY MF, DYKXHOORN DM et al: siRNA-directed inhibition of HIV-1 infection. Nat. Med. (2002) 8:681–686.
- SONG E, LEE SK, DYKXHOORN DM et al.: Sustained small interfering RNA-mediated human immunodeficiency virus type 1 inhibition in primary macrophages.
- •Virol (2003) 77:7174–7181.
- MARTINEZ MA, GUTIERREZ A, ARMAND-UGON M et al.: Suppression of chemokine receptor expression by RNA interference allows for inhibition of HIV-1 replication. AIDS (2002) 16:2385–2390.
- POLURI A, MAANEN MV, SUTTON RE: Genetic therapy for HIV/ AIDS. Expert Opin. Biol. The]: (2003) 3:951–963.
- POESCHLA E, CORBEAU P, WONG-STAAL F: Development of HIV vectors for anti-HIV gene therapy. Proc. Natl. Acad. Sci. USA (1996) 93:11395–11399.
- UCHIDA N, SUTTON RE, FRIERA AM et al.: HIV, but not murine leukemia virus, vectors mediate high efficiency gene transfer into freshly isolated GO/G1 human hematopoietic stem cells. Proc. Nati Acad. Sci. USA (1998) 95:11939–11944.
- MIYOSHI H, SMITH KA, MOSIER DE, VERMA IM, TORBETT BE: Transduction of human CD34+ cells that mediate long- term engraftment of NOD/SCID mice by HIV vectors. Science (1999) 283:682–686.
- GATLIN J, PADGETT A, MELKUS MW,KELLY PF, GARCIA JV: Long-term engraftment of nonobese diabetic/severe combined immunodeficient mice with human CD34+ cells transduced by a self-inactivating human immunodeficiency virus type 1 vector. Hum. Gene The]: (2001) 12:1079–1089.
- LEE MT, COBURN GA, MCCLURE MO, CULLEN BR: Inhibition of human immunodeficiency virus Type 1 replication in primary macrophages by using Tat- or CCR5-specific small interfering RNAs expressed from a lentivirus vector. Virol (2003) 77: 11964-11972.
- •Demonstrates that lentiviral RNAi vectors effectively inhibit HIV-1 replication in primary human macrophages.
- BANERJEA A, LI MJ, BAUER G et al: Inhibition of HIV-1 by lentiviral vector-transduced siRNAs in T lymphocytes differentiated in SCID-hu mice and CD34+ progenitor cell-derived macrophages. MM. Ther. (2003) 8:62–71.
- ••Proof of concept for combating AIDS viareconstituting an HIV-resistant immune system using lentiviral RNAi vector-transduced CD34+ HSCs.
- HILLEMAN MR: Critical overview and outlook: pathogenesis, prevention, and treatment of hepatitis and hepatocarcinoma caused by hepatitis B virus. Vaccine (2003) 21:4626–4649.
- WILSON JA, JAYASENA S, KHVOROVA A et al.: RNA interference blocks gene expression and RNA synthesis from hepatitis C replicons propagated in human liver cells. Proc. Nati Acad. Sci. USA (2003) 100:2783–2788.
- RACANELLI V, REHERMANN B: Hepatitis C virus infection: when silence is deception. Trends Immunol. (2003) 24:456–464.
- FLAMM SL: Chronic hepatitis C virus infection. JAMA (2003) 289:2413–2417.
- YOKOTA T, SAKAMOTO N, ENOMOTO N et al.: Inhibition of intracellular hepatitis C virus replication by synthetic and vector-derived small interfering RNAs. EMBO Rep. (2003) 4:602–608.
- SEO MY, ABRIGNANI S, HOUGHTON M, HAN JH: Small interfering RNA-mediated inhibition of hepatitis C virus replication in the human hepatoma cell line Huh-7. J. Vim/. (2003) 77:810–812.
- RANDALL G, GRAKOUI A, RICE CM: Clearance of replicating hepatitis C virus replicon RNAs in cell culture by small interfering RNAs. Proc. Natl. Acad. Sci. USA (2003) 100:235–240.
- KAPADIA SB, BRIDEAU-ANDERSEN A,CHISARI FV: Interference of hepatitis C virus RNA replication by short interfering RNAs. Proc. Natl. Acad. Sci. USA (2003) 100:2014–2018.
- SHLOMAI A, SHAUL Y: Inhibition of hepatitis B virus expression and replication by RNA interference. Hepatology (2003) 37:764–770.
- HAMASAKI K, NAKAO K, MATSUMOTO K et al.: Short interfering RNA-directed inhibition of hepatitis B virus replication. FEBS Lett. (2003) 543:51–54.
- MCCAFFREY AP, NAKAI H, PANDEY K et al: Inhibition of hepatitis B virus in mice by RNA interference. Nat. Biotechnol (2003) 21:639–644.
- ••One of two reports demonstrating thatsiRNA blocks HBV replication in mice.
- YING C, DE CLERCQ E, NEYTS J: Selective inhibition of hepatitis B virus replication by RNA interference. Biochem. Biophys. Res. Commun. (2003) 309:482–484.
- GILADI H, KETZINEL-GILAD M, RIVKIN L et al.: Small interfering RNA inhibits hepatitis B virus replication in mice. Mol Ther. (2003) 8:769–776.
- ••One of two reports demonstrating thatsiRNA blocks HBV replication in mice.
- PFEIFER A, KESSLER T, YANG M et al.: Transduction of liver cells by lentiviral vectors: analysis in living animals by fluorescence imaging. Mol The]: (2001) 3:319–322.
- PARK F: Correction of bleeding diathesis without liver toxicity using arenaviral-pseudotyped HIV-1-based vectors in hemophilia A mice. Hum. Gene Ther. (2003) 14:1489–1494.
- DAMM-WELK C, FUCHS U, WOSSMANN W, BORKHARDT A: Targeting oncogenic fusion genes in leukemias and lymphomas by RNA interference. Semin. Cancer Biol. (2003) 13:283–292.
- KOVAR H, BAN J, POSPISILOVA S: Potentials for RNAi in sarcoma research and therapy: Ewing's sarcoma as a model. Semin. Cancer Biol. (2003) 13:275–281.
- DUURSMA AM, AGAMI R: Ras interference as cancer therapy. Semin. Cancer Biol. (2003) 13:267–273.
- YOSHINOUCHI M, YAMADA T, KIZAKI M et al.: ha vitro and in vivo growth suppression of human papillomavirus 16-positive cervical cancer cells by e6 siRNA. Mol. Ther. (2003) 8:762–768.
- ••Demonstrates that siRNA-mediatedoncogene silencing reduces turnourigenicity in vivo.
- SCHERR M, BATTMER K, WINKLER T et al.: Specific inhibition of bcr-abl gene expression by small interfering RNA. Blood (2003) 101:1566–1569.
- WOHLBOLD L, VAN DER KUIP H, MIETHING C et al.: Inhibition of bcr-abl gene expression by small interfering RNA sensitizes for imatinib mesylate (5TI571). Blood(2003) 102:2236–2239.
- ••Highlights potential usefulness of combinedRNAi/chemotherapeutic interventions.
- WOOD MJ, TRULZSCH B, ABDELGANY A, BEESON D: Ribozymes and siRNA for the treatment of diseases of the nervous system. Carr: Opin. Mol The]: (2003) 5:383–388.
- WOOD MJ, TRULZSCH B, ABDELGANY A, BEESON D: Therapeutic gene silencing in the nervous system. Hum. Mol Genet. (2003) 12(Spec. No. 2):R279–R284.
- ESCARPE P, ZAYEK N, CHIN P et al: Development of a sensitive assay for detection of replication-competent recombinant lentivirus in large-scale HIV- based vector preparations. Ma Ther. (2003) 8:332–341.
- KOHN DB, SADELAIN M, DUNBAR C et al.: American Society of Gene Therapy (ASGT) ad hoc subcommittee on retroviral-mediated gene transfer to hematopoietic stem cells. Ma The]: (2003) 8:180–187.
- ••Important commentary on retroviral genetherapy of HSCs.
- HACEIN-BEY-ABINA S, LE DEIST F, CARLIER F et al.: Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy. N. Engl. J. Med. (2002) 346:1185–1193.
- AIUTI A, SLAVIN S, AKER M et al: Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning. Science (2002) 296:2410–2413.
- HACEIN-BEY-ABINA S, VON KALLE C, SCHMIDT M et al.: A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N Engl. J. Med. (2003) 348:255–256.
Websites
- http://www.ambion.com
- •• An informative RNAi resource that provides up-to-date practical information regarding siRNA and RNAi vectors.
- http://www.genscript.com
- http://www.imgenex.com
- http://www.invivogen.com
- http://www.oligoengine.com
- http://www.promega.com
- http://www.bdbiosciences.com/clontech/